Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

• Authors: KOESSLER T.; ALSINA M.; ARNOLD D.; BEN-AHARON I.; LUTZ M. P.; OBERMANNOVÁ Radka; PEETERS M.; SCLAFANI F.; SMYTH E.; VALLE J. W.; WAGNER A. D.; WYRWICZ L.; FONTANA E.; MOEHLER M.
• Year of publication: 2021
• Type: Article in Periodical
• Magazine / Source: British journal of cancer
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.nature.com/articles/s41416-021-01474-y
• Doi: http://dx.doi.org/10.1038/s41416-021-01474-y
• Keywords: Gastrointestinal tract cancer; ASCO-GI 2021
• Description: Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.